Penn’s one-stop solution for technology commercialization and entrepreneurship
I’m a Faculty Member or Researcher
I’m with a Company
I’m an Entrepreneur
I want to:
Translating Discoveries
PCI helps to translate discoveries and ideas created at the University of Pennsylvania into new products and businesses for societal benefit.
We actively facilitate a broad range of technology development connections between Penn and the private sector. Whether the end result is a technology license, an R&D alliance, or the formation of a new venture, PCI serves as a dedicated one-stop shop for commercial partnering with Penn.
Read the report hereInnovation Stories
Penn Faculty Receive ARPA-H Awards for Gene Therapy Research
The Office of the Chief Innovation Officer (OCINO) at Penn announced its first investments from its newly launched $10 million StartUP Fund.
The inaugural investments will support three Penn faculty-founded companies as they further develop and commercialize their technologies. The companies include:
- Vasowatch, co-founded by Stefanie Modri, MSN, RN, C-MNN, C-OB, Clinical Adjunct Instructor at Penn Nursing, and James Weimer, PhD, former Penn Engineering faculty member
- OneFiltr, co-founded by Troy Olsson, PhD, Professor of Electrical and Systems Engineering at Penn Engineering
- Peptaris, Inc., co-founded by César de la Fuente, PhD, Presidential Assistant Professor at Penn, and Marcelo Der Torossian Torres, PhD, Research Assistant Professor of Psychiatry at Penn Medicine
The StartUP Fund offers up to $250,000 to eligible companies with at least one founder who is a Penn faculty member or researcher currently affiliated with Penn. Applications are accepted on a rolling basis and reviewed quarterly.
Kira Pharmaceuticals to Merge with Jasper Therapeutics
Jasper Therapeutics recently completed its merger with Kira Pharmaceuticals, a startup company co-founded by Penn Medicine’s Wenchao Song, PhD, Professor of Systems Pharmacology and Translational Therapeutics at Penn Medicine. The combined company is focused on the development of biologic therapies for immune-mediated diseases, including complement pathway programs originating from Kira and the laboratory of Dr. Song. As part of the agreement, Kira out-licensed two complement-pathway assets to Mirador, which is expected to initiate clinical development later this year.
Learn More
Read the Latest News from PCI on LinkedIn
Available Technologies
Find technology opportunities by sector or search:
Nanotechnology | Antibody | Optics & Photonics | Medical Devices | COVID-19 | Immunology | Oncology | Materials | Bioengineering | Neurodegenerative Diseases
View all technologies
Upcoming Events
All Events